Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- INTERNATIONAL JOURNAL OF UROLOGY26(2) · pp.192 · 2019
- 피인용
- Web of Science 18Scopus 18
- FWCI (Scopus)
- 1.63
- JCR IF
- JCR 2018 2.107
- ISSN
- 0919-8172
저자
- Zhang, Zhichao제1저자Andrology Center, Peking University First Hospital, Peking University, Beijing, China
- Li, HanzhongPeking Union Medical College Hospital, Beijing, China
- Zhang, XiaodongBeijing Chaoyang Hospital, Capital Medical University, Beijing, China
- Dai, YutianNanjing Drum Tower Hospital, Nanjing, China
- 박현준Department of Urology, Pusan National University Hospital, Busan, South Korea
- Jiann, Bang-PingKaohsiung Veterans General Hospital, Kaohsiung, Taiwan
- Li, PengEli Lilly Suzhou Pharmaceutical, Shanghai, China
- Lou, YingEli Lilly Suzhou Pharmaceutical, Shanghai, China
- Ye, Zhangqun교신저자Department of Urology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
- Viktrup, LarsLilly Research Laboratories, Eli Lilly and Company, Indianapolis, United States
초록
Objective To evaluate the efficacy and safety of tadalafil in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction. Methods The present phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study was carried out at 40 study centers in the Asia-Pacific region (mainland China, Taiwan and Korea; NCT01937871). Participants were randomized to receive a placebo (n = 361), tadalafil 5 mg (n = 362) or tamsulosin 0.2 mg (n = 185) in a 2:2:1 ratio for 12 weeks. Results A total of 909 Asian men were randomized into three groups. After 12 weeks of treatment, a statistically significant improvement in least squares mean change from baseline in total International Prostate Symptom Score was observed in the tadalafil versus the placebo group (-5.49 vs -4.08, respectively; P < 0.001). A statistically significant improvement in the change from baseline for the International Index of Erectile Function-Erectile Function domain score, was observed in tadalafil compared with the placebo at 12 weeks (5.24 vs 1.88, respectively; P < 0.001). A significant improvement was observed in the change from baseline in the percentage of "Yes" responses to Sexual Encounter Profile questions 2 and 3 in the tadalafil versus placebo group at 12 weeks (23.87% vs 10.90%; P vs 15.96%; P < 0.001, respectively). Safety results were consistent with the known tadalafil safety profile. Conclusions Tadalafil is efficacious and well tolerated in the treatment of Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction.
키워드
Asiaerectile dysfunctionlower urinary tract symptomsprostatic hyperplasiatadalafilKOREAN MENA-DAYSECONDARYTHERAPY12-WEEKLUTS
식별자
- Scopus EID
- 2-s2.0-85055490507
- WoS UID
- 000457782400006



로그인
연구물 목록으로